Nanocrystals of Poorly Soluble Drugs for Oral Administration

At present about 40% of the drugs being in the development pipelines are poorly soluble, even up to 60% of compounds coming directly from synthesis are poorly soluble [1]. Poor solubility is in most cases associated with poor bioavailability. According to the Noyes-Whitney law the dissolution velocity dc/dt depends on the saturation solubility cs. There are two basic approaches to overcome the bioavailability problems of these drugs: 1. Increase of saturation solubility (e.g. by complex formation) 2. Increase of dissolution velocity. The first approach was of limited successs as clearly demonstrated by the low number of products on the market based on such technologies. A much more straight forward